Fundz

Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment

PRIVATEJan 17, 2024

Amount Raised

$50 Million

Round Type

Series B

BostonBiotechnologyHealth CareTherapeuticsPharmaceutical

Investors

Center For Technology Licensing At Cornell UniversityBristol Myers SquibbPags GroupDuquesne

Description

Ratio Therapeutics Inc. announces the close of its $50M Series B financing, bringing the total raised to date to over $90 million, with continued participation from Series A leads and new investors PagsGroup, Bristol Myers Squibb, and the Center for Technology Licensing at Cornell University.

Who else raised in Therapeutics and Pharmaceutical around the same time

Companies in the same sectors as Ratio Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Parabilis Medicines raised $145M (Series E) on March 1, 2024.
  • Crinetics Pharmaceuticals raised $350M on March 1, 2024.
  • vTv Therapeutics Inc. raised $51M on February 27, 2024.
  • XORTX Therapeutics raised $2.5M (Seed) on February 19, 2024.
  • Biofrontera raised $8M on February 19, 2024.
  • AIM ImmunoTech raised $3.3M (Seed) on February 16, 2024.

Who to call at Ratio Therapeutics, and when

A new round usually means Ratio Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Ratio Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Ratio Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Ratio Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Ratio Therapeutics

Location

1 617-371-8898 One Design Center

Boston, Massachusetts, United States

About

Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. With headquarters and laboratories in Boston, the company currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development. Ratio's proprietary R&D platforms, Trillium™ and Macropa™, enable the development of fit-for-purpose radiopharmaceuticals for therapy and imaging that possess pharmacokinetic modulation, thereby improving drug availability, tumor delivery, and tumor loading. The company maintains a strong commitment to manufacturing through its collaboration with PharmaLogic and its own state-of-the-art facility located in Salt Lake City, Utah, ensuring reliable supply and quality in radiopharmaceutical production. Ratio plans to initiate a Phase 1/2 trial to evaluate the safety, tolerability and efficacy of its FAP-targeted radiotherapeutic as a treatment for patients with relapsed or refractory soft tissue sarcoma. The company is also advancing other programs in its pipeline, including the pre-clinical assessment of [Lu-177]-RTX2358 across several cancer indications to explore its broader therapeutic potential and expects its Granzyme B-targeted agent for PET imaging program to move into the clinic in 2026.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Ratio Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Ratio Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Ratio Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.